Please login to the form below

Not currently logged in
Email:
Password:

Bayer enters agreement with Celera

Bayer Schering Pharma AG, Germany, has entered into an exclusive licence agreement with US biotech company Celera Corporation

Bayer Schering Pharma AG, Germany, has entered into an exclusive licence agreement with US biotech company Celera Corporation. Bayer will pay Celera a one-off fee for exclusive access to five cancer target molecules and additional payments for particular development and commercial milestones. Celera will also receive royalties based on net sales of commercialised products.

"We look forward to exploring the full potential of these promising target candidates with regard to therapeutic interference for anti-tumour therapy as well as in in-vivo diagnostic imaging", said Professor Khusru Asadullah head of target discovery at Bayer Schering Pharma. 

Celera Genomics was founded in 1988 with the aim of sequencing and assembling the human genome. It was acquired by Applera Corporation but separated from that company and started trading on Nasdaq in July 2008. It recently moved its base from Maryland Washington, to Alameda, California and is now focused on developing personalised diagnostics and medicines. Steve Ruben, vice president of proteomic research at the company, said: "This agreement combines the strength of our novel proteomics target discovery platform with Bayer Schering Pharma's expertise in research and development." 

30th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics